MovDisordV3, Main, Exploration, bibRecord, 006422

The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

Identifieur interne : 006422 ( Main/Exploration ); précédent : 006421; suivant : 006423

The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

Auteurs : Gibb [Royaume-Uni] ; M. Terruli [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; P. Jenner [Royaume-Uni] ; C. D. Marsden [Royaume-Uni]

Source :

Movement Disorders [ 0885-3185 ] ; 1989.

RBID : ISTEX:CEC046FBC5AA89331FC5A8CAC9DCD7A3A2CB95FB

English descriptors

KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine, Animals, Axons (drug effects), Brain (drug effects), Callitrichinae, Common marmoset, Corpus Striatum (drug effects), Dose-Response Relationship, Drug, Hypothalamus (drug effects), Ischaemia, Lewy body, Neural Pathways (drug effects), Neuroglia (drug effects), Neurons (drug effects), Parkinson Disease, Secondary (chemically induced), Parkinson's disease, Pyridines (toxicity), Substantia Nigra (drug effects), Substantia nigra, Thalamic Nuclei (drug effects).
MESH :
- chemical , toxicity : Pyridines.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Axons, Brain, Corpus Striatum, Hypothalamus, Neural Pathways, Neuroglia, Neurons, Substantia Nigra, Thalamic Nuclei.
- Animals, Callitrichinae, Dose-Response Relationship, Drug.

Abstract

Six young adult marmosets received 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in multiple doses (total 8–16 mg/kg over 2–13 days) sufficient to produce a parkinsonian syndrome and were killed up to 3.5 months later. Cellular changes were found in the substantia nigra, ventral tegmental area, and hypothalamus. The earliest histological abnormalities were axonal swellings in proximal parts of nigrostriatal axons. Subsequent changes in the substantia nigra were reduced Nissl staining, reduced cell volume, and aggregation and loss of melanin granules. Other effects were reduced nuclear and nucleolar volumes, depletion of cells, and hyperplasia of glial cells. Shrunken cytoplasm and nuclei stained uniformaly with eosin, and no cells showed cytoplasmic swellings or inclusions. These cellular alterations, with nuclear chages resembling karyolysis, do not occur in Parkinson's disease, which is characterised by Lewy body inclusions and signs of chromatolysis. The rapid appearance of axonal swellings, disruption of Nissl substance, and cell shrinkage suggest an insult to energy producing mechanisms. In this study, the absence of histological evidence of toxicity in the locus coeruleus and also in the substantia innominata and in serotonergic cell groups is unlike the more wide‐spread degenerative changes of Parkinson's disease.

Url:

https://api.istex.fr/document/CEC046FBC5AA89331FC5A8CAC9DCD7A3A2CB95FB/fulltext/pdf

DOI: 10.1002/mds.870040109

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title>
<author><name sortKey="Gibb" sort="Gibb" uniqKey="Gibb" last="Gibb">Gibb</name>
</author>
<author><name sortKey="Terruli, M" sort="Terruli, M" uniqKey="Terruli M" first="M." last="Terruli">M. Terruli</name>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CEC046FBC5AA89331FC5A8CAC9DCD7A3A2CB95FB</idno>
<date when="1989" year="1989">1989</date>
<idno type="doi">10.1002/mds.870040109</idno>
<idno type="url">https://api.istex.fr/document/CEC046FBC5AA89331FC5A8CAC9DCD7A3A2CB95FB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000851</idno>
<idno type="wicri:Area/Istex/Curation">000851</idno>
<idno type="wicri:Area/Istex/Checkpoint">004452</idno>
<idno type="wicri:doubleKey">0885-3185:1989:Gibb:the:evolution:and</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:2494438</idno>
<idno type="wicri:Area/PubMed/Corpus">005005</idno>
<idno type="wicri:Area/PubMed/Curation">005005</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004F56</idno>
<idno type="wicri:Area/Ncbi/Merge">004032</idno>
<idno type="wicri:Area/Ncbi/Curation">004032</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004032</idno>
<idno type="wicri:doubleKey">0885-3185:1989:Gibb W:the:evolution:and</idno>
<idno type="wicri:Area/Main/Merge">009775</idno>
<idno type="wicri:Area/Main/Curation">006422</idno>
<idno type="wicri:Area/Main/Exploration">006422</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</title>
<author><name sortKey="Gibb" sort="Gibb" uniqKey="Gibb" last="Gibb">Gibb</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Department of Neuropathology, National Hospitals for Nervous Diseases, Maida Vale</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Terruli, M" sort="Terruli, M" uniqKey="Terruli M" first="M." last="Terruli">M. Terruli</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Department of Neuropathology, National Hospitals for Nervous Diseases, Maida Vale</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Department of Neuropathology, National Hospitals for Nervous Diseases, Maida Vale</wicri:orgArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<orgName>National Hospital for Neurology and Neurosurgery</orgName>
</affiliation>
</author>
<author><name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<affiliation wicri:level="3"><country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
<wicri:orgArea>Department of Neuropathology, National Hospitals for Nervous Diseases, Maida Vale</wicri:orgArea>
</affiliation>
</author>
<author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<affiliation wicri:level="2"><country>Royaume-Uni</country>
<placeName><region type="country">Angleterre</region>
</placeName>
<wicri:cityArea>MRC Movement Disorders Research Group, University Department of Neurology and Parkinson's Disease Society Research Centre, Institute of Psychiatry and King's College Hospital Medical School, London</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1989">1989</date>
<biblScope unit="vol">4</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="53">53</biblScope>
<biblScope unit="page" to="74">74</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">CEC046FBC5AA89331FC5A8CAC9DCD7A3A2CB95FB</idno>
<idno type="DOI">10.1002/mds.870040109</idno>
<idno type="ArticleID">MDS870040109</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
<term>1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine</term>
<term>Animals</term>
<term>Axons (drug effects)</term>
<term>Brain (drug effects)</term>
<term>Callitrichinae</term>
<term>Common marmoset</term>
<term>Corpus Striatum (drug effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Hypothalamus (drug effects)</term>
<term>Ischaemia</term>
<term>Lewy body</term>
<term>Neural Pathways (drug effects)</term>
<term>Neuroglia (drug effects)</term>
<term>Neurons (drug effects)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson's disease</term>
<term>Pyridines (toxicity)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia nigra</term>
<term>Thalamic Nuclei (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Pyridines</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Axons</term>
<term>Brain</term>
<term>Corpus Striatum</term>
<term>Hypothalamus</term>
<term>Neural Pathways</term>
<term>Neuroglia</term>
<term>Neurons</term>
<term>Substantia Nigra</term>
<term>Thalamic Nuclei</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callitrichinae</term>
<term>Dose-Response Relationship, Drug</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Six young adult marmosets received 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine in multiple doses (total 8–16 mg/kg over 2–13 days) sufficient to produce a parkinsonian syndrome and were killed up to 3.5 months later. Cellular changes were found in the substantia nigra, ventral tegmental area, and hypothalamus. The earliest histological abnormalities were axonal swellings in proximal parts of nigrostriatal axons. Subsequent changes in the substantia nigra were reduced Nissl staining, reduced cell volume, and aggregation and loss of melanin granules. Other effects were reduced nuclear and nucleolar volumes, depletion of cells, and hyperplasia of glial cells. Shrunken cytoplasm and nuclei stained uniformaly with eosin, and no cells showed cytoplasmic swellings or inclusions. These cellular alterations, with nuclear chages resembling karyolysis, do not occur in Parkinson's disease, which is characterised by Lewy body inclusions and signs of chromatolysis. The rapid appearance of axonal swellings, disruption of Nissl substance, and cell shrinkage suggest an insult to energy producing mechanisms. In this study, the absence of histological evidence of toxicity in the locus coeruleus and also in the substantia innominata and in serotonergic cell groups is unlike the more wide‐spread degenerative changes of Parkinson's disease.</div>
</front>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement><li>Londres</li>
</settlement>
<orgName><li>National Hospital for Neurology and Neurosurgery</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Gibb" sort="Gibb" uniqKey="Gibb" last="Gibb">Gibb</name>
</region>
<name sortKey="Jenner, P" sort="Jenner, P" uniqKey="Jenner P" first="P." last="Jenner">P. Jenner</name>
<name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">Andrew Lees (neurologue)</name>
<name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name>
<name sortKey="Terruli, M" sort="Terruli, M" uniqKey="Terruli M" first="M." last="Terruli">M. Terruli</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006422 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006422 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:CEC046FBC5AA89331FC5A8CAC9DCD7A3A2CB95FB
   |texte=   The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.